Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis.
Apr 30, 2015 at 10:00 AM ET
Ocera Reports Pipeline Progress and First Quarter 2015 Financial Results
Jun 23, 2015
JMP Securities Life Sciences Conference